Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1688 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Prosensa Begins PRO044 Phase I/II Study

Prosensa said that the objective of the open label, dose-escalating study is to evaluate the safety and tolerability of the systemic delivery of PRO044 in 12 DMD patients